Cargando…
Safety and efficacy of intensive vs. guideline antiplatelet therapy in high‐risk patients with recent ischemic stroke or transient ischemic attack: rationale and design of the Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke (TARDIS) trial (ISRCTN47823388)
RATIONALE: The risk of recurrence following a stroke or transient ischemic attack is high, especially immediately after the event. HYPOTHESIS: Because two antiplatelet agents are superior to one in patients with non‐cardioembolic events, more intensive treatment might be even more effective. SAMPLE...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4855643/ https://www.ncbi.nlm.nih.gov/pubmed/26079743 http://dx.doi.org/10.1111/ijs.12538 |
Ejemplares similares
-
Statistical analysis plan for the ‘Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke’ (TARDIS) trial
por: Bath, Philip M W, et al.
Publicado: (2015) -
Acute dual antiplatelet therapy for minor ischaemic stroke or transient ischaemic attack
por: Wang, Yongjun, et al.
Publicado: (2019) -
Dual Antiplatelet Therapy after Noncardioembolic Ischemic Stroke or Transient Ischemic Attack: Pros and Cons
por: Hong, Keun-Sik
Publicado: (2014) -
Dual vs. mono antiplatelet therapy for acute ischemic stroke or transient ischemic attack with evidence of large artery atherosclerosis
por: Lin, Chun-Jen, et al.
Publicado: (2022) -
Stopping “transient ischemic attacks” by antiplatelet withdrawal
por: Palaiodimou, Lina, et al.
Publicado: (2021)